haloperidol has been researched along with Depressive Disorder in 126 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Depressive Disorder: An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This was a 17-country investigation of 1996 patients with schizophrenia or a related diagnosis randomly assigned to a blinded, comparative trial of the novel antipsychotic agent olanzapine (5-20 mg/d) or the conventional D2 antagonist haloperidol (5-20 mg/d)." | 9.08 | Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. ( Lu, Y; Sanger, TM; Thieme, ME; Tollefson, GD, 1998) |
| "One schizophrenic and two manic-depressive patients who after the administration of zotepine, a new antipsychotic and antimanic drug, developed alopecia areata, a kind of autoimmune disease, are reported." | 7.68 | Three cases of alopecia areata induced by zotepine. ( Ishikura, T; Jibiki, I; Kubota, T, 1993) |
| "Comorbid cocaine abuse adversely affects clinical outcomes in schizophrenia." | 6.71 | Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. ( Campbell, EC; Caroff, SN; Cornish, J; Kondrich, J; Mann, SC; O'Brien, C; Sayers, SL, 2005) |
| "Pharmacologic dissection of borderline personality disorder patients into affective and schizotypal subtypes could not be demonstrated." | 6.67 | Efficacy of phenelzine and haloperidol in borderline personality disorder. ( Cornelius, J; George, A; Nathan, S; Perel, JM; Soloff, PH; Ulrich, RF, 1993) |
| "Haloperidol was also significantly superior to thiothixene in Cognitive Disturbance on the HPRSD." | 6.65 | Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia. ( Abuzzahab, FS; Zimmerman, RL, 1982) |
| "A 34-year-old woman treated for a major depressive disorder experienced NMS with a phenothiazine." | 5.30 | Carbamazepine in the treatment of neuroleptic malignant syndrome. ( Cottencin, O; Goudemand, M; Maron, M; Rascle, C; Thomas, P; Vaiva, G, 1998) |
| "We suggest that alopecia areata is associated with haloperidol." | 5.29 | Alopecia areata associated with haloperidol. ( Ishikura, T; Jibiki, I; Kubota, T, 1994) |
| "This was a 17-country investigation of 1996 patients with schizophrenia or a related diagnosis randomly assigned to a blinded, comparative trial of the novel antipsychotic agent olanzapine (5-20 mg/d) or the conventional D2 antagonist haloperidol (5-20 mg/d)." | 5.08 | Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. ( Lu, Y; Sanger, TM; Thieme, ME; Tollefson, GD, 1998) |
| "To establish the differential indication of trazodone and to find the predictors of its efficacy, we conducted a study in which 45 patients with major depressive disorder and 75 patients with acute schizophrenia were randomly assigned under double-blind conditions to either 400 mg trazodone daily, 150 mg amitriptyline daily, 20 mg haloperidol daily, or placebo daily." | 5.06 | Experimental examination of trazodone. ( Klieser, E; Lehmann, E, 1989) |
| "Treatment of acute mania with second-generation antipsychotics has been claimed to involve a lower risk of switch to depression than haloperidol." | 4.89 | Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. ( Capapey, J; Colom, F; Goikolea, JM; Grande, I; Sanchez-Moreno, J; Torres, I; Undurraga, J; Valentí, M; Vieta, E, 2013) |
| "Lithium carbonate is the single most important long-term treatment for recurrent affective disorders." | 4.76 | Lithium. ( DePaulo, JR, 1984) |
| " In order to determine the specificity of these observations, similar studies were conducted in subjects with major depressive disorder and in monkeys after 9-12 months of haloperidol treatment." | 3.71 | Lamina-specific deficits in parvalbumin-immunoreactive varicosities in the prefrontal cortex of subjects with schizophrenia: evidence for fewer projections from the thalamus. ( Cruz, DA; Lewis, DA; Melchitzky, DS; Pierri, JN, 2001) |
| "Haloperidol is unlikely to confound the results of studies investigating disease-related alterations in the levels of a broad range of cytokines and soluble cytokine receptors in schizophrenia." | 3.69 | Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. ( Fenzel, T; Hinze-Selch, D; Kraus, T; Mullington, J; Pollmächer, T; Schuld, A, 1997) |
| "One schizophrenic and two manic-depressive patients who after the administration of zotepine, a new antipsychotic and antimanic drug, developed alopecia areata, a kind of autoimmune disease, are reported." | 3.68 | Three cases of alopecia areata induced by zotepine. ( Ishikura, T; Jibiki, I; Kubota, T, 1993) |
| "A 50-year-old man presented with hyperosmolar non-ketotic diabetic coma associated with the neuroleptic malignant syndrome (NMS) after intramuscular treatment with haloperidol." | 3.68 | Neuroleptic malignant syndrome presenting as hyperosmolar non-ketotic diabetic coma. ( Balzan, M; Cacciottolo, JM, 1992) |
| "A case reported here of Haloperidol-induced neutropenia demonstrates one of many important drug reactions to which the elderly may be predisposed." | 3.67 | Neuroleptic-induced neutropenia in the elderly. ( Andolsek, K; Hanlon, J; Jurivich, DA, 1987) |
| "Baclofen, commonly used to reduce severe muscle spasms in patients with spinal cord injuries, is also active in the brain." | 3.66 | A possible neurochemical basis for the neuropsychiatric aspects of baclofen therapy. ( Keegan, DL; Kirby, AR; Richardson, JS, 1983) |
| " Sixty-three depressed women (major depressive disorder) and 21 paranoid-hallucinatory women have been studied while on antidepressant (clomipramine) or neuroleptic (haloperidol) treatment, respectively." | 3.66 | The TSH-response to TRH: A possible predictor of outcome to antidepressant and neuroleptic treatment. ( Aschauer, H; Koinig, G; Langer, G; Resch, F; Schönbeck, G, 1983) |
| " Dosage was increased stepwise from 100mg up to 400mg trimipramine and from 100mg up to 200mg amitriptyline combined with 2mg up to 7." | 2.74 | Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol--a double-blind multicenter trial. ( Ackl, N; Hatzinger, M; Held, K; Holsboer, F; Holsboer-Trachsler, E; Ising, M; Kaschka, W; Kasper, S; Konstantinidis, A; Künzel, HE; Sonntag, A; Steiger, A; Uhr, M; Yassouridis, A, 2009) |
| "Comorbid cocaine abuse adversely affects clinical outcomes in schizophrenia." | 2.71 | Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. ( Campbell, EC; Caroff, SN; Cornish, J; Kondrich, J; Mann, SC; O'Brien, C; Sayers, SL, 2005) |
| " A total of 123 patients (62 RIS; 61 HAL/AMI) were included; the mean daily dosage at endpoint was 6." | 2.69 | Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. ( Benkert, O; Hillert, A; Müller, MJ; Müller-Siecheneder, F; Szegedi, A; Wetzel, H, 1998) |
| "Haloperidol at 4 mg/day was coadministered for 1 week, and blood samplings were taken before and after the coadministration." | 2.68 | Increases in plasma concentration of m-chlorophenylpiperazine, but not trazodone, with low-dose haloperidol. ( Ishida, M; Kaneko, S; Mihara, K; Ohkubo, T; Osanai, T; Otani, K; Sugawara, K; Suzuki, A; Yasui, N, 1997) |
| "Haloperidol was prescribed for 68 percent of the patients." | 2.68 | Neuroleptic treatment of elderly patients. ( Alvir, JM; Kane, JM; Lieberman, JA; Saltz, BL; Woerner, MG, 1995) |
| "Pharmacologic dissection of borderline personality disorder patients into affective and schizotypal subtypes could not be demonstrated." | 2.67 | Efficacy of phenelzine and haloperidol in borderline personality disorder. ( Cornelius, J; George, A; Nathan, S; Perel, JM; Soloff, PH; Ulrich, RF, 1993) |
| "Haloperidol was also significantly superior to thiothixene in Cognitive Disturbance on the HPRSD." | 2.65 | Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia. ( Abuzzahab, FS; Zimmerman, RL, 1982) |
| "We studied the incidence of akathisia in two populations of newly admitted schizophrenic patients: one group was treated with haloperidol and the other group was treated with thiothixene hydrochloride." | 2.65 | Akathisia with haloperidol and thiothixene. ( Marder, SR; May, PR; Van Putten, T, 1984) |
| "Early identification and treatment of panic disorder might help to avoid unnecessary repeated emergency department visits, and at the same time reduce the associated high risk of suicide and other psychiatric disorders such as depression as well as drug and alcohol abuse." | 2.38 | [Emergency: the internist as psychiatrist]. ( Knüsel, H, 1993) |
| "Choreoathetosis is suggested to be a sign of lithium toxicity, almost always accompanied by other signs of neurotoxicity, such as delirium and cerebellar dysfunction." | 2.38 | Choreoathetosis: a sign of lithium toxicity. ( Reed, SM; Timmerman, I; Wise, MG, 1989) |
| "However, interictal delirium is uncommon in absence of risk factors." | 1.38 | Delayed onset and prolonged interictal delirium following electroconvulsive therapy. ( Praharaj, SK; Selvaraj, AG, 2012) |
| "Haloperidol was discontinued, but mirtazapine was continued, and the vivid dream activity persisted; however, reality testing when awake was intact." | 1.36 | Acute psychosis associated with dissociated sleep-wakefulness state after mirtazapine treatment. ( Felthous, AR; Hoevet, R; Wenger, PJ, 2010) |
| "The structure of depressive syndrome was influenced by the number of previous psychotic episodes The combination of antipsychotics and antidepressants was effective in the treatment of depressive symptoms in schizophrenic patients during the postpsychotic phase." | 1.35 | [Depression in schizophrenia]. ( Ivanets, NN; Kinkul'kina, MA, 2008) |
| "Imipramine doses were adjusted to attain a predefined fixed plasma level." | 1.35 | Efficacy of imipramine in psychotic versus nonpsychotic depression. ( Birkenhager, TK; Bruijn, JA; Moleman, P; Mulder, PG; van den Broek, WW, 2008) |
| "A 34-year-old woman treated for a major depressive disorder experienced NMS with a phenothiazine." | 1.30 | Carbamazepine in the treatment of neuroleptic malignant syndrome. ( Cottencin, O; Goudemand, M; Maron, M; Rascle, C; Thomas, P; Vaiva, G, 1998) |
| "We report five cases of neuroleptic malignant syndrome (NMS) with psychotic symptoms treated with electroconvulsive therapy (ECT)." | 1.30 | Electroconvulsive therapy for the treatment of neuroleptic malignant syndrome with psychotic symptoms: a report of five cases. ( Ishiguro, T; Nisijima, K, 1999) |
| "Doctors' prescription and dosing behaviour was investigated using data from 9 clinical trials in 550 patients treated with psychotropics." | 1.29 | Correct titration of non-drugs and some other methodological issues. ( Beneke, M; Fritze, J; Rasmus, W; Rød, IS, 1994) |
| "We suggest that alopecia areata is associated with haloperidol." | 1.29 | Alopecia areata associated with haloperidol. ( Ishikura, T; Jibiki, I; Kubota, T, 1994) |
| " We discuss a possible relation between serotonin syndrome and a highly dosed combination therapy with moclobemide." | 1.29 | [Depressive stupor--malignant neuroleptic syndrome--serotonin syndrome. A case contribution to a difficult differential diagnosis]. ( König, F; Löble, M; Wolfersdorf, M, 1996) |
| "The relationship between NMS and catatonia and possible therapeutic decisions are discussed." | 1.29 | Neuroleptic malignant syndrome and catatonia. A report of three cases. ( Altavista, MC; Cavallari, S; Lubich, L; Raja, M, 1994) |
| "A case is reported, in which fatal pulmonary embolism complicated the course of a neuroleptic malignant syndrome (NMS)." | 1.28 | [Malignant neuroleptic syndrome: complete anticoagulant treatment or not?]. ( van Agtmael, MA; van Harten, PN, 1992) |
| "A case was described in which neuroleptic malignant syndrome reoccurred as the result of an inadvertent rechallenge in a woman with mild mental retardation." | 1.28 | Recurrence of neuroleptic malignant syndrome via an inadvertent rechallenge in a woman with mental retardation. ( Boyd, RD, 1992) |
| "Cerebrotendinous xanthomatosis is a genetically transmitted disease that is associated with deposition of cholestanol in the central nervous system and Achilles tendons." | 1.27 | Depression in a patient with dementia secondary to cerebrotendinous xanthomatosis. ( Shapiro, S, 1983) |
| "Twenty-nine patients were treated with haloperidol decanoate, the dosage ranging from 100 to 300 mg i." | 1.27 | The use of depot neuroleptic haloperidol decanoate. ( Fernando, J; Jones, GG; Krishna Raju, R; Stanley, RO, 1984) |
| "Sulpiride isomers were studied in the rat in four behavioural models of depression which are thought to be influenced by neuroleptics in different ways." | 1.27 | Antidepressant versus neuroleptic activities of sulpiride isomers on four animal models of depression. ( Dall'Olio, R; Gaggi, R; Gandolfi, O; Montanaro, N; Vaccheri, A, 1984) |
| " Subacute and chronic administration of imipramine (4 or 15 mg/kg) decreased immobility of rats in the behavioral despair model." | 1.27 | The effects of carbamazepine on two animal models of depression. ( Barros, HM; Leite, JR, 1987) |
| "This suggests that the depressive syndrome among schizophrenics is not manifested as a result of pharmaceutical action." | 1.27 | [Depressive syndromes within the scope of schizophrenic diseases]. ( Heim, M, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 47 (37.30) | 18.7374 |
| 1990's | 55 (43.65) | 18.2507 |
| 2000's | 18 (14.29) | 29.6817 |
| 2010's | 6 (4.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horiuchi, Y | 1 |
| Ishikawa, M | 1 |
| Kaito, N | 1 |
| Iijima, Y | 1 |
| Tanabe, Y | 1 |
| Ishiguro, H | 1 |
| Arinami, T | 1 |
| Chen, C | 1 |
| Nakagawa, S | 1 |
| Kitaichi, Y | 1 |
| An, Y | 1 |
| Omiya, Y | 1 |
| Song, N | 1 |
| Koga, M | 1 |
| Kato, A | 1 |
| Inoue, T | 1 |
| Kusumi, I | 1 |
| Taoka, H | 1 |
| Hamamura, T | 1 |
| Endo, S | 1 |
| Miyata, S | 1 |
| Toma, K | 1 |
| Ishihara, T | 1 |
| Kuroda, S | 1 |
| Künzel, HE | 1 |
| Ackl, N | 1 |
| Hatzinger, M | 1 |
| Held, K | 1 |
| Holsboer-Trachsler, E | 1 |
| Ising, M | 1 |
| Kaschka, W | 1 |
| Kasper, S | 1 |
| Konstantinidis, A | 1 |
| Sonntag, A | 1 |
| Uhr, M | 1 |
| Yassouridis, A | 1 |
| Holsboer, F | 1 |
| Steiger, A | 1 |
| Ivanets, NN | 1 |
| Kinkul'kina, MA | 1 |
| Felthous, AR | 1 |
| Wenger, PJ | 1 |
| Hoevet, R | 1 |
| Preskorn, SH | 1 |
| Selvaraj, AG | 1 |
| Praharaj, SK | 1 |
| Goikolea, JM | 1 |
| Colom, F | 1 |
| Torres, I | 1 |
| Capapey, J | 1 |
| Valentí, M | 1 |
| Undurraga, J | 1 |
| Grande, I | 1 |
| Sanchez-Moreno, J | 1 |
| Vieta, E | 1 |
| Grunze, H | 1 |
| Marcuse, A | 1 |
| Schärer, LO | 1 |
| Born, C | 1 |
| Walden, J | 1 |
| Koh, PO | 1 |
| Bergson, C | 1 |
| Undie, AS | 1 |
| Goldman-Rakic, PS | 1 |
| Lidow, MS | 1 |
| Emsley, RA | 1 |
| Buckley, P | 1 |
| Jones, AM | 1 |
| Greenwood, MR | 1 |
| KAMENSKAIA, VM | 1 |
| ALEKSANDROVSKII, IuA | 1 |
| RUGGERINI, R | 1 |
| ZECCA, C | 1 |
| Dunlop, BW | 1 |
| Sternberg, M | 1 |
| Phillips, LS | 1 |
| Andersen, J | 1 |
| Duncan, E | 1 |
| Alevizos, B | 1 |
| Sayers, SL | 1 |
| Campbell, EC | 1 |
| Kondrich, J | 1 |
| Mann, SC | 1 |
| Cornish, J | 1 |
| O'Brien, C | 1 |
| Caroff, SN | 1 |
| Bloch, MH | 1 |
| Landeros-Weisenberger, A | 1 |
| Kelmendi, B | 1 |
| Coric, V | 1 |
| Bracken, MB | 1 |
| Leckman, JF | 1 |
| Duarte, FS | 1 |
| Lach, G | 1 |
| Martins, PR | 1 |
| Romeiro, GA | 1 |
| de Lima, TC | 1 |
| Birkenhager, TK | 1 |
| van den Broek, WW | 1 |
| Mulder, PG | 1 |
| Moleman, P | 1 |
| Bruijn, JA | 1 |
| Borsini, F | 1 |
| Nowakowska, E | 1 |
| Samanin, R | 1 |
| Schrader, G | 1 |
| Hicks, EP | 1 |
| Vaccheri, A | 1 |
| Dall'Olio, R | 1 |
| Gaggi, R | 1 |
| Gandolfi, O | 1 |
| Montanaro, N | 1 |
| Keegan, DL | 1 |
| Richardson, JS | 1 |
| Kirby, AR | 1 |
| Möller, HJ | 4 |
| Kissling, W | 3 |
| Herberger, B | 2 |
| Kuss, HJ | 1 |
| DePaulo, JR | 1 |
| Goode, DJ | 1 |
| Manning, AA | 1 |
| Langer, G | 2 |
| Aschauer, H | 2 |
| Koinig, G | 2 |
| Resch, F | 2 |
| Schönbeck, G | 2 |
| Manberg, PJ | 1 |
| Carter, RG | 1 |
| Campbell, M | 1 |
| Small, AM | 1 |
| Green, WH | 1 |
| Jennings, SJ | 1 |
| Perry, R | 1 |
| Bennett, WG | 1 |
| Anderson, L | 1 |
| Keshavan, MS | 1 |
| Dittrich, R | 1 |
| Garbutt, JC | 2 |
| Loosen, PT | 2 |
| Van Putten, T | 1 |
| May, PR | 1 |
| Marder, SR | 1 |
| Bottermann, P | 1 |
| Holcomb, HH | 1 |
| Sternberg, DE | 1 |
| Heninger, GR | 1 |
| Fernando, J | 1 |
| Krishna Raju, R | 1 |
| Jones, GG | 1 |
| Stanley, RO | 1 |
| Shapiro, S | 1 |
| Abuzzahab, FS | 1 |
| Zimmerman, RL | 1 |
| Scapagnini, U | 1 |
| Canonico, PL | 1 |
| Nicoletti, F | 1 |
| Patti, F | 1 |
| Fiore, L | 1 |
| Tigano, G | 1 |
| Clementi, G | 1 |
| Gessa, GL | 1 |
| Bristol, JH | 1 |
| Davidson, J | 1 |
| Miller, R | 1 |
| Wingfield, M | 1 |
| Dougherty, G | 1 |
| Katz, RJ | 1 |
| Sibel, M | 1 |
| von Zerssen, D | 1 |
| Bech, P | 1 |
| Shapiro, RW | 1 |
| Sihm, F | 1 |
| Nielsen, BM | 1 |
| Sørensen, B | 1 |
| Rafaelsen, OJ | 1 |
| Woerner, MG | 1 |
| Alvir, JM | 1 |
| Kane, JM | 1 |
| Saltz, BL | 2 |
| Lieberman, JA | 1 |
| Mauri, MC | 2 |
| Bravin, S | 1 |
| Mantero, M | 1 |
| Invernizzi, G | 1 |
| Kubota, T | 2 |
| Ishikura, T | 2 |
| Jibiki, I | 2 |
| Raja, M | 1 |
| Altavista, MC | 1 |
| Cavallari, S | 1 |
| Lubich, L | 1 |
| Wolfersdorf, M | 2 |
| König, F | 2 |
| Straub, R | 1 |
| Newcomer, JW | 1 |
| Miller, LS | 1 |
| Faustman, WO | 1 |
| Wetzel, MW | 1 |
| Vogler, GP | 1 |
| Csernansky, JG | 1 |
| Beneke, M | 1 |
| Rasmus, W | 1 |
| Rød, IS | 1 |
| Fritze, J | 1 |
| Johnson, TW | 1 |
| Polger, S | 1 |
| Emerich, DF | 1 |
| Freeman, TB | 1 |
| Cahill, DW | 1 |
| Sanberg, PR | 1 |
| Vita, A | 1 |
| Giobbio, GM | 1 |
| Ferrara, A | 1 |
| Dieci, M | 1 |
| Bitetto, A | 1 |
| Altamura, AC | 1 |
| Spivak, B | 3 |
| Radwan, M | 3 |
| Brandon, J | 3 |
| Baruch, Y | 1 |
| Stawski, M | 1 |
| Tyano, S | 3 |
| Weizman, A | 3 |
| Knüsel, H | 1 |
| Soloff, PH | 2 |
| Cornelius, J | 1 |
| George, A | 2 |
| Nathan, S | 2 |
| Perel, JM | 2 |
| Ulrich, RF | 1 |
| Byerly, MJ | 1 |
| Christensen, RC | 1 |
| Evans, OL | 1 |
| Anderson, BG | 1 |
| Reker, D | 1 |
| Cooper, T | 1 |
| Amore, M | 1 |
| Giordani, L | 1 |
| Giorgetti, G | 1 |
| Zazzeri, N | 1 |
| King, DJ | 2 |
| Burke, M | 1 |
| Lucas, RA | 1 |
| Maes, M | 1 |
| De Meester, I | 1 |
| Scharpe, S | 1 |
| Desnyder, R | 1 |
| Ranjan, R | 1 |
| Meltzer, HY | 1 |
| Benazzi, F | 1 |
| Löble, M | 1 |
| Melamed, Y | 1 |
| Karniel, E | 1 |
| Szor, H | 1 |
| Mihara, K | 2 |
| Otani, K | 2 |
| Ishida, M | 1 |
| Yasui, N | 1 |
| Suzuki, A | 1 |
| Ohkubo, T | 1 |
| Osanai, T | 1 |
| Kaneko, S | 2 |
| Sugawara, K | 1 |
| Lewis, CF | 1 |
| DeQuardo, JR | 1 |
| Tandon, R | 1 |
| Tollefson, GD | 2 |
| Beasley, CM | 1 |
| Tran, PV | 1 |
| Street, JS | 1 |
| Krueger, JA | 1 |
| Tamura, RN | 1 |
| Graffeo, KA | 1 |
| Thieme, ME | 2 |
| Pollmächer, T | 1 |
| Hinze-Selch, D | 1 |
| Fenzel, T | 1 |
| Kraus, T | 1 |
| Schuld, A | 1 |
| Mullington, J | 1 |
| Sanger, TM | 1 |
| Lu, Y | 1 |
| Thomas, P | 1 |
| Maron, M | 1 |
| Rascle, C | 1 |
| Cottencin, O | 1 |
| Vaiva, G | 1 |
| Goudemand, M | 1 |
| Müller-Siecheneder, F | 1 |
| Müller, MJ | 1 |
| Hillert, A | 1 |
| Szegedi, A | 1 |
| Wetzel, H | 1 |
| Benkert, O | 1 |
| Khisti, RT | 1 |
| Mandhane, SN | 1 |
| Chopde, CT | 1 |
| Abouesh, A | 1 |
| Hobbs, WR | 1 |
| Gannon, MA | 1 |
| O'Sullivan, P | 1 |
| Kelley, ME | 1 |
| van Kammen, DP | 1 |
| Allen, DN | 1 |
| Nisijima, K | 2 |
| Ishiguro, T | 1 |
| Goodman, WK | 1 |
| Greene, YM | 1 |
| McDonald, WM | 1 |
| Duggan, J | 1 |
| Cooper, R | 1 |
| Bonomo, V | 1 |
| Fogliani, AM | 1 |
| Shapiro, J | 1 |
| Belmaker, RH | 1 |
| Biegon, A | 1 |
| Seker, A | 1 |
| Agam, G | 1 |
| Gerbershagen, MU | 1 |
| Ito, WD | 1 |
| Wappler, F | 1 |
| Fiege, M | 1 |
| Schulte am Esch, J | 1 |
| Janicak, PG | 1 |
| Keck, PE | 1 |
| Davis, JM | 1 |
| Kasckow, JW | 1 |
| Tugrul, K | 1 |
| Dowd, SM | 1 |
| Strong, J | 1 |
| Sharma, RP | 1 |
| Strakowski, SM | 1 |
| Lewis, DA | 1 |
| Cruz, DA | 1 |
| Melchitzky, DS | 1 |
| Pierri, JN | 1 |
| Stárková, L | 1 |
| Mrna, B | 1 |
| van den Bosch, RJ | 1 |
| van Asma, MJ | 1 |
| Rombouts, R | 1 |
| Louwerens, JW | 1 |
| van Agtmael, MA | 1 |
| van Harten, PN | 1 |
| Uehlinger, C | 1 |
| Barrelet, L | 1 |
| Touabi, M | 1 |
| Baumann, P | 1 |
| Egorov, AY | 1 |
| Nikolaenko, NN | 1 |
| Balzan, M | 1 |
| Cacciottolo, JM | 1 |
| Mazure, CM | 2 |
| Nelson, JC | 3 |
| Jatlow, PI | 3 |
| Bowers, MB | 2 |
| Boyd, RD | 1 |
| Hogan, TP | 1 |
| Awad, AG | 1 |
| Hirayama, M | 1 |
| Okada, M | 1 |
| Fukushima, Y | 1 |
| Besson, JA | 1 |
| Holland, J | 1 |
| Wheeldon, T | 1 |
| Ebmeier, KP | 1 |
| Molcho, A | 1 |
| Ohring, R | 1 |
| Robinson, S | 1 |
| Rosca, P | 1 |
| Durst, R | 1 |
| Shai, U | 1 |
| Ghinea, C | 1 |
| Schmidt, U | 1 |
| Nir, I | 1 |
| Bartur, P | 1 |
| Grieger, TA | 1 |
| Clayton, AH | 1 |
| Roca, RP | 1 |
| Blackman, MR | 1 |
| Ackerley, MB | 1 |
| Harman, SM | 1 |
| Gregerman, RI | 1 |
| Austin, LS | 1 |
| Arana, GW | 1 |
| Melvin, JA | 1 |
| Reed, SM | 1 |
| Wise, MG | 1 |
| Timmerman, I | 1 |
| Kramer, MS | 1 |
| Vogel, WH | 1 |
| DiJohnson, C | 1 |
| Dewey, DA | 1 |
| Sheves, P | 1 |
| Cavicchia, S | 1 |
| Little, P | 1 |
| Schmidt, R | 1 |
| Kimes, I | 1 |
| Klieser, E | 1 |
| Lehmann, E | 1 |
| Lin, KM | 1 |
| Poland, RE | 1 |
| Fu, P | 1 |
| Nuccio, I | 1 |
| Lesser, IM | 1 |
| Schulz, PM | 1 |
| Cornelius, JR | 1 |
| Herring, J | 1 |
| Bulens, C | 1 |
| Meerwaldt, JD | 1 |
| van der Wildt, GJ | 1 |
| Keemink, CJ | 1 |
| Tipermas, A | 1 |
| Barros, HM | 1 |
| Leite, JR | 1 |
| Herrmann, N | 1 |
| Lieff, SJ | 1 |
| O'Brien, P | 1 |
| Ravaris, CL | 1 |
| Sateia, MJ | 1 |
| Beroza, KW | 1 |
| Noordsy, DL | 1 |
| Brinck-Johnsen, T | 1 |
| Ananth, J | 1 |
| Binz, U | 1 |
| Wendt, G | 1 |
| Spahn, H | 1 |
| Heim, M | 2 |
| Devaney, NM | 1 |
| Cooper, SJ | 1 |
| Price, LH | 1 |
| Jurivich, DA | 1 |
| Hanlon, J | 1 |
| Andolsek, K | 1 |
| Liskow, BI | 1 |
| Maisami, M | 1 |
| Sohmer, BH | 1 |
| Coyle, JT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial.[NCT00564564] | Phase 4 | 21 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)[NCT02422290] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| An Open-Label Trial of Epidiolex in the Treatment of Obsessive Compulsive Disorder and Related Disorders: Proof of Concept Study[NCT04978428] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-04-14 | Recruiting | ||
| Open Label Study for the Use of Transcranial Ultrasound Treatment of Obsessive-Compulsive Disorder[NCT04775875] | 30 participants (Anticipated) | Interventional | 2020-12-01 | Enrolling by invitation | |||
| Effectiveness of Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients: A 8-week Open-label Prospective, Non-comparative Study[NCT01399450] | Phase 4 | 11 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia[NCT03075657] | Phase 4 | 120 participants (Actual) | Interventional | 2017-05-01 | Completed | ||
| Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia[NCT00156715] | Phase 4 | 23 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)[NCT00130923] | Phase 4 | 95 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| A Double-Blind, Placebo-Controlled Study of Brexpiprazole in the Treatment of Borderline Personality Disorder.[NCT03418675] | Phase 2 | 80 participants (Actual) | Interventional | 2018-11-26 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The CY-BOCS is a semi-structured measure of OCD severity with excellent inter-rater reliability, internal consistency, and test-retest reliability. It is validated in those starting at age 7 and used in studies up to age 20. The CYBOCS differs from the adult YBOCS only in its use of simpler language. The CY-BOCS consists of 10 items which are summed up to derive the total CY-BOCS score. The total score ranges from 0-40 with higher scores indicating greater severity of OCD symptoms. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CY-BOCS Baseline | CY-BOCS Day 14 | |
| Ketamine Treatment Group | 29.00 | 26.20 |
The CGI-S is a clinician rated 7-point rating scale for the severity of a participant's illness relative to the clinician's experience of working with this particular population. The score ranges from 1-7 with higher scores indicating greater illness severity. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CGI-S Baseline | CGI-S Day 14 | |
| Ketamine Treatment Group | 5.80 | 5.00 |
"The OCD-VAS is a one-item unipolar scale to assess OCD symptoms over a rapid time frame (No obsessions to Constant obsessions). The scale ranges from 0-10 with higher scores indicating higher presence of obsessions." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| OCD-VAS Baseline | OCD-VAS Day 14 | |
| Ketamine Treatment Group | 5.00 | 5.00 |
"The Y-BOCCS is self-report scale which assesses OCD symptoms on a 5-point likert scale (None to Extreme). It consists of 10 items which are summed up to derive the total Y-BOCCS score. The total score ranges from 0-40 with higher scores indicating higher prevalence of OCD symptoms." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Y-BOCCS Baseline | Y-BOCCS Day 14 | |
| Ketamine Treatment Group | 18.25 | 16.50 |
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
The main outcome measure of clinical symptoms was the Positive and Negative Symptoms Scale. This is a 30 item scale for assessing patients diagnosed with schizophrenia. Each item is rated on a 1 (absent) to 7 (extreme) scale. The minimum total score is 30 and the maximum is 210. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| QUET | 65.5 |
Timeline Follow-back (TLFB) procedure was used at screening and baseline to establish current substance use, and it was also used weekly during the course of the study to assess continued alcohol and other substance use. TLFB cosisted of using a calendar and sasking participants to report alcohol and other drug use since last visit. At the screening visit, the TLFB was done for the four weeks prior to the visit. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Drinking Days per Week (Mean) |
|---|---|
| QUET | 2.7 |
Frequency of drinking days is obtained each week retrospectively as the number of drinking days during the prior week (assessed using the Timeline Followback). Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 2.84 |
| Oral Risperidone Aka Risperdal | 3.46 |
A rater assesses social, occupational and psychological functioning on a hypothetical continuum of mental health - illness (using Global Assessment of Functioning); scores range from 100 to 1, where higher values represent a better outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of impairment (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 50.8 |
| Oral Risperidone Aka Risperdal | 49.9 |
A rater assesses positive and negative symptoms of schizophrenia using a 30-item scale (Positive and Negative Symptom Score) Scores range from 30 to 210, where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of symptoms (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 78.2 |
| Oral Risperidone Aka Risperdal | 75.5 |
A rater assesses the severity of illness and global impression using a scale from 1 to 7 (Clinical Global Impression), where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal unit of severity (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 4.02 |
| Oral Risperidone Aka Risperal | 3.96 |
Frequency of heavy drinking days is obtained each week retrospectively as the number of heavy drinking days during the prior week (assessed by the Timeline Followback Scale). A heavy drinking day is defined as 4 or more drinks per day for a female and 5 or more drinks per day for a male. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | heavy drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | -.11 |
| Oral Risperidone Aka Risperal | .68 |
Number of participants with medication adherence (defined as taking medication at least 75% of the days in the treatment period). (NCT00130923)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 43 |
| Oral Risperidone Aka Risperdal | 28 |
A clinician-administered assessment of anxiety that will be assessed at all study visits (Visit 1-Visit 8). Changes in scores from baseline to final visit will be assessed. Higher scores (up to 56) indicate higher levels of anxiety, with 0 being no symptoms of anxiety. (NCT03418675)
Timeframe: assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to Week 12) is reported
| Intervention | change in score on a scale (Mean) |
|---|---|
| Placebo | -2.41 |
| Rexulti | -4.88 |
A clinician-administered assessment of depression that will be assessed at all study visits (Visits 1-8). Higher total scores indicate higher levels of depression (up to 52), while a score of 0 would indicate no depressive symptoms. (NCT03418675)
Timeframe: Assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to week 12) is reported
| Intervention | change in score on a scale (Mean) |
|---|---|
| Placebo | -2.09 |
| Rexulti | -3.81 |
A self-report assessment of impulsivity that will be assessed at baseline and visit 8. The BIS is composed of 30 items describing common impulsive or non-impulsive (for reverse scored items) behaviors and preferences. Items are scored on a 4-point scale: (Rarely/Never = 1, Occasionally = 2, Often = 3, Almost Always/Always = 4). These scores are summed to produce an overall impulsivity score ranging from 30 (not impulsive) to 120 (extremely impulsive). (NCT03418675)
Timeframe: Baseline (Visit 1), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Visit 1 | Visit 8 | |
| Placebo | 76.53 | 68.13 |
| Rexulti | 72.27 | 70.5 |
A self rated scale used to measure severity and change. The first 12 items of the scale are on a scale from 1-5, with 5 meaning that the item caused extreme distress, severe difficulties in relationships, and/or kept them from getting things done. The lowest rating (1) means it caused little or no problems. Items 13-15 (positive behaviors) are rated according to frequency. Completed at every visit. (NCT03418675)
Timeframe: Assessed at Visits 1 to 8, change in scores from Visit 1 to Visit 8 (baseline to week 12) is reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Visit 1 | Visit 8 | |
| Placebo | 40.90 | 29.15 |
| Rexulti | 40.54 | 23.15 |
"A self-report scale measuring suicidality. Subjects will complete the scale at all visits. Subjects are asked about suicidal thoughts. If answers are no, rater can proceed to suicidal behavior section where subject is asked about any non-suicidal self injurious behavior. If yes, subject is asked about intensity of ideations. In the event of serious threat to themselves, the subject will be escorted to the emergency room. Total score indicates severity of suicidal ideation and behavior, with lower scores representing lower levels of suicidality and higher scores representing higher levels of suicidality. A score of 0 would reflect no suicidality present, whereas a maximum score of 5 would reflect active suicidal ideation with intent to act." (NCT03418675)
Timeframe: Baseline (Visit 1), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Visit 1 | Visit 8 | |
| Placebo | 1.15 | 0.23 |
| Rexulti | 0.73 | 0.08 |
A short-structured interview that assesses comorbid psychiatric disorders according to the DSM 5 criteria. This assessment will be done during the baseline visit. (NCT03418675)
Timeframe: Baseline (Week 1)
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Major Depressive Episode (Current) | Major Depressive Episode (Past) | Manic Episode (Current) | Manic Episode (Past) | Hypomanic Episode (Current) | Bipolar I Disorder (Current) | Bipolar I Disorder (Past) | Bipolar II Disorder (Current) | Bipolar II Disorder (Past) | Panic Disorder (Current) | Panic Disorder (Lifetime) | Agoraphobia (Current) | Social Anxiety Disorder (Current) | Obsessive Compulsive Disorder (Current) | Post Traumatic Stress Disorder (Current) | Alcohol Use Disorder (Past 12 months) | Substance Use Disorder (Past 12 months) | Any Psychotic Disorder (Current) | Any Psychotic Disorder (Lifetime) | Major Depressive Disorder with Psychotic Features (Current) | Major Depressive Disorder with Psychotic Features (Past) | Anorexia Nervosa (current) | Bulimia Nervosa (Current) | Binge Eating Disorder (Current) | Generalized Anxiety Disorder (Current) | Antisocial Personality Disorder (Lifetime) | ADHD Combined Type (Current) | ADHD Inattentive Type (Current) | ADHD Hyperactive Type (Current) | Tourette's Syndrome (Lifetime) | Persistent Motor Tic Disorder (Lifetime) | Provisional Vocal Tic Disorder (Lifetime) | Provisional Tic Disorder (Lifetime) | Specific Phobia | Body Dysmorphic Disorder (Current) | |
| Placebo | 16 | 12 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 6 | 11 | 7 | 6 | 3 | 9 | 13 | 11 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 10 | 8 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 4 | 3 |
| Rexulti | 18 | 18 | 2 | 3 | 0 | 0 | 0 | 0 | 1 | 6 | 10 | 9 | 9 | 3 | 12 | 8 | 8 | 0 | 1 | 0 | 0 | 1 | 4 | 4 | 15 | 4 | 4 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 2 |
A self-report assessment of patient perceived quality of life that will be assessed at baseline and visit 8. Higher scores indicate a higher quality of life, whereas lower scores indicate a lower quality of life. Participants are asked to rate the importance of each domain on a 3-point scale ranging from 1=not important to 3=very important, and to rate how satisfied they are with that domain on a 6-point scale, ranging from -3=very dissatisfied to +3=very satisfied. In scoring, importance ratings are multiplied by satisfaction ratings to produce weighted satisfaction scores for each of the 16 domains. Weighted satisfaction scores are summed and divided by the number of domains that were rated as important or very important to produce a raw score, which is then converted to a t-score, which provides a proxy measurement for perceived quality of life. T-scores range from very low perceived quality of life (0-36) to high perceived quality of life (58-77). (NCT03418675)
Timeframe: Baseline (Week 1), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Visit 1 | Visit 8 | |
| Placebo | 28.89 | 30.75 |
| Rexulti | 28.70 | 35.71 |
A self-report scale assessing Borderline Personality severity that will be assessed at all visits.This scale is assessing severity and change in BPD symptoms. This is a 9-item scale measuring severity of different aspects of Borderline Personality Disorder, with each item rated on a 0-4 scale, 0=no symptoms, 4=severe symptoms. Total scores range from 0-36. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Visit 7 | Visit 8 | |
| Placebo | 18.2 | 12.8 | 10.7 | 10.7 | 9.7 | 9.6 | 8.7 | 9.3 |
| Rexulti | 17.6 | 10.9 | 7.9 | 8.0 | 7.0 | 6.6 | 6.0 | 5.8 |
Subjects will complete the SDS at all visits. The change in scores from baseline to study completion will be assessed. The scale itself assesses the level of disability from borderline personality disorder (or target disorder) with higher scores indicating a more debilitating disorder. Scores range from 0-30. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Visit 7 | Visit 8 | |
| Placebo | 17.3 | 13.3 | 11.5 | 12.4 | 11.7 | 11.2 | 12.0 | 12.7 |
| Rexulti | 15.8 | 10.7 | 7.8 | 7.8 | 7.0 | 7.9 | 6.9 | 7.7 |
An instrument that helps evaluate a broad range of psychological problems and symptoms of Borderline Personality Disorder psychopathology. This will be assessed at baseline and visit 8.The 115 items are rated by using a 5-step Likert scale (0=not at all, 4=very strong) and provide a global picture of borderline psychopathology. Global scores of borderline psychopathology are calculated by summing 12 items and range from 0-48. Higher scores indicate more severe symptoms of Borderline Personality Disorder. (NCT03418675)
Timeframe: Baseline, Visit 8 (Week 12)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Visit 1 | Visit 8 | |
| Placebo | 26.17 | 20.25 |
| Rexulti | 25.42 | 14.21 |
A clinician-administered scale assessing Borderline Personality Scale severity at all study visits. Scores range from 0-36. Higher scores represent worse Borderline Personality Disorder severity, and lower scores represent milder Borderline Personality Disorder severity. (NCT03418675)
Timeframe: Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8)
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | Visit 7 | Visit 8 | |
| Placebo | 14.9 | 7.6 | 4.7 | 6 | 4.2 | 5.7 | 5 | 8.4 |
| Rexulti | 14.9 | 6.7 | 5.3 | 4.4 | 4.5 | 4.9 | 4 | 3.1 |
9 reviews available for haloperidol and Depressive Disorder
| Article | Year |
|---|---|
CNS drug development. Part I: The early period of CNS drugs.
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Anxiety Disorders; Bipolar Disorder; Central | 2010 |
Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disord | 2013 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
Lithium.
Topics: Aggression; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, C | 1984 |
[Emergency: the internist as psychiatrist].
Topics: Crisis Intervention; Depressive Disorder; Diagnosis, Differential; Diazepam; Emergencies; Family Pra | 1993 |
[Pharmacological treatment of delusional depression].
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Delusions; Depressive Disorde | 1996 |
Obsessive-compulsive disorder: diagnosis and treatment.
Topics: Anxiety Disorders; Behavior Therapy; Clinical Trials as Topic; Combined Modality Therapy; Comorbidit | 1999 |
Choreoathetosis: a sign of lithium toxicity.
Topics: Aged; Athetosis; Chorea; Clonazepam; Delirium; Depressive Disorder; Drug Therapy, Combination; Femal | 1989 |
Clomipramine: an antiobsessive drug.
Topics: Anxiety; Behavior Therapy; Clinical Trials as Topic; Clomipramine; Compulsive Behavior; Depressive D | 1986 |
25 trials available for haloperidol and Depressive Disorder
| Article | Year |
|---|---|
Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol--a double-blind multicenter trial.
Topics: Adrenocorticotropic Hormone; Adult; Amitriptyline; Anti-Dyskinesia Agents; Antidepressive Agents, Tr | 2009 |
Nefazodone in psychotic unipolar and bipolar depression: a retrospective chart analysis and open prospective study on its efficacy and safety versus combined treatment with amitriptyline and haloperidol.
Topics: Adult; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; An | 2002 |
Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder; Dibenzothiazepines; Double- | 2003 |
Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Addictive; Benzodiazepines; Cocaine-Related | 2005 |
[Controlled study on the possible benefits of combination therapy with chlorimipramine and haloperidol inpatients with endogenous depression].
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Clomipramine; Depressive Disorder; Drug Combinati | 1984 |
Comparison of bupropion alone and with haloperidol in schizo-affective disorder, depressed type.
Topics: Adolescent; Adult; Bupropion; Depressive Disorder; Drug Therapy, Combination; Female; Haloperidol; H | 1983 |
Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder.
Topics: Aggression; Child; Child Behavior Disorders; Clinical Trials as Topic; Depressive Disorder; Double-B | 1984 |
A dramatic behavioral response to thyrotropin-releasing hormone following low-dose neuroleptics.
Topics: Adult; Borderline Personality Disorder; Clinical Trials as Topic; Depressive Disorder; Double-Blind | 1984 |
Akathisia with haloperidol and thiothixene.
Topics: Adult; Akathisia, Drug-Induced; Anxiety Disorders; Depressive Disorder; Dose-Response Relationship, | 1984 |
Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia.
Topics: Adolescent; Adult; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Female; Halop | 1982 |
Failure of isocarboxazid and haloperidol to alleviate delusional depression in a pilot study.
Topics: Adult; Delusions; Depressive Disorder; Double-Blind Method; Female; Haloperidol; Humans; Isocarboxaz | 1982 |
Neuroleptic treatment of elderly patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Brief Psychiatric Rating Scale; Dementia; Depressive | 1995 |
Efficacy of phenelzine and haloperidol in borderline personality disorder.
Topics: Adult; Borderline Personality Disorder; Comorbidity; Depressive Disorder; Double-Blind Method; Femal | 1993 |
Increases in plasma concentration of m-chlorophenylpiperazine, but not trazodone, with low-dose haloperidol.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Cytochrome P-450 CYP2D6 Inhib | 1997 |
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depre | 1997 |
Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Depressive Disorder; Double-Blind Method; | 1998 |
Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Depr | 1998 |
Citalopram and haloperidol for psychotic depression.
Topics: Adult; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Haloperidol; Humans; Male | 2000 |
A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Female; Hal | 2001 |
Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures.
Topics: Adolescent; Adult; Anxiety Disorders; Chlorpromazine; Depressive Disorder; Female; Haloperidol; Huma | 1992 |
Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial.
Topics: Adolescent; Adult; Amitriptyline; Benztropine; Clinical Trials as Topic; Depressive Disorder; Desipr | 1989 |
Experimental examination of trazodone.
Topics: Adult; Amitriptyline; Anxiety; Depression; Depressive Disorder; Double-Blind Method; Female; Haloper | 1989 |
Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response.
Topics: Amitriptyline; Borderline Personality Disorder; Depressive Disorder; Follow-Up Studies; Haloperidol; | 1989 |
Clomipramine: an antiobsessive drug.
Topics: Anxiety; Behavior Therapy; Clinical Trials as Topic; Clomipramine; Compulsive Behavior; Depressive D | 1986 |
Controlled trial on the possible advantages of a combined therapy with maprotiline and haloperidol in endogenous depression.
Topics: Adult; Anthracenes; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Drug Therapy | 1986 |
93 other studies available for haloperidol and Depressive Disorder
| Article | Year |
|---|---|
Experimental evidence for the involvement of PDLIM5 in mood disorders in hetero knockout mice.
Topics: Adaptor Proteins, Signal Transducing; Animals; Behavior, Animal; Bipolar Disorder; Brain; Cell Line; | 2013 |
The role of medial prefrontal corticosterone and dopamine in the antidepressant-like effect of exercise.
Topics: Animals; Antidepressive Agents; Corticosterone; Depression; Depressive Disorder; Dopamine; Glucocort | 2016 |
Antipsychotics possessing antidepressive efficacy increase Golf protein in rat striatum.
Topics: Amisulpride; Animals; Antipsychotic Agents; Benzodiazepines; Blotting, Western; Clozapine; Corpus St | 2008 |
[Depression in schizophrenia].
Topics: Acute Disease; Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzodiazepines; Chi-S | 2008 |
Acute psychosis associated with dissociated sleep-wakefulness state after mirtazapine treatment.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Depressive Disorder, Major; Dreams; Ha | 2010 |
Delayed onset and prolonged interictal delirium following electroconvulsive therapy.
Topics: Cholinesterase Inhibitors; Delirium; Depressive Disorder; Donepezil; Electroconvulsive Therapy; Foll | 2012 |
Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia.
Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Blotting, Western; Cell Count; Contractile Proteins | 2003 |
[CLINICO-ELECTROENCEPHALOGRAPHIC STUDY OF THE EFFECT OF HALOPERIDOL ON SCHIZOPHRENICS].
Topics: Catatonia; Depression; Depressive Disorder; Drug Therapy; Electroencephalography; Haloperidol; Human | 1964 |
[HALOPERIDOL IN PREMEDICATION FOR ELECTROSHOCK THERAPY].
Topics: Convulsive Therapy; Delusions; Depression; Depressive Disorder; Electricity; Electroconvulsive Thera | 1964 |
Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Cohort Studies; Depressive Disorder; Diabetes | 2003 |
Dependence and chronic psychosis with D-nor-pseudoephedrine.
Topics: Antipsychotic Agents; Appetite; Appetite Depressants; Benzodiazepines; Central Nervous System Stimul | 2003 |
Evidence for the involvement of the monoaminergic system in the antidepressant-like action of two 4-amine derivatives of 10,11-dihydro-5H-dibenzo [a,d] cycloheptane in mice evaluated in the tail suspension test.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Cycloheptanes; Depressive Dis | 2008 |
Efficacy of imipramine in psychotic versus nonpsychotic depression.
Topics: Adult; Affective Disorders, Psychotic; Aged; Antidepressive Agents; Data Interpretation, Statistical | 2008 |
Effect of repeated treatment with desipramine in the behavioral "despair" test in rats: antagonism by "atypical" but not "classical" neuroleptics or antiadrenergic drugs.
Topics: Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Butyrophenones; Chlorpromazine; Clonidi | 1984 |
Narcolepsy, paranoid psychosis, major depression, and tardive dyskinesia.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder; Dextroamphetamine; Dyskinesi | 1984 |
Antidepressant versus neuroleptic activities of sulpiride isomers on four animal models of depression.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Apomorphine; Behavior, Animal; Body Temperatur | 1984 |
A possible neurochemical basis for the neuropsychiatric aspects of baclofen therapy.
Topics: Adult; Baclofen; Bipolar Disorder; Brain; Delusions; Depressive Disorder; Dose-Response Relationship | 1983 |
The TSH-response to TRH: A possible predictor of outcome to antidepressant and neuroleptic treatment.
Topics: Adolescent; Adult; Aged; Clomipramine; Depressive Disorder; Female; Haloperidol; Humans; Middle Aged | 1983 |
Bupropion in the treatment of psychotic depression: two case reports.
Topics: Adult; Antidepressive Agents; Bupropion; Depressive Disorder; Drug Therapy, Combination; Female; Hal | 1984 |
TSH-response patterns to TRH stimulation may indicate therapeutic mechanisms of antidepressant and neuroleptic drugs.
Topics: Adult; Clomipramine; Depressive Disorder; Female; Haloperidol; Humans; Prognosis; Psychiatric Status | 1984 |
Serial application of clonidine tests during antidepressive treatment with chlorimipramine.
Topics: Adult; Clomipramine; Clonidine; Depressive Disorder; Drug Therapy, Combination; Female; Growth Hormo | 1984 |
Effects of electroconvulsive therapy on mood, parkinsonism, and tardive dyskinesia in a depressed patient: ECT and dopamine systems.
Topics: Aged; Brain; Delusions; Depressive Disorder; Dopamine; Dyskinesia, Drug-Induced; Electroconvulsive T | 1983 |
The use of depot neuroleptic haloperidol decanoate.
Topics: Bipolar Disorder; Depressive Disorder; Haloperidol; Humans; Prognosis; Psychotic Disorders; Schizoph | 1984 |
Depression in a patient with dementia secondary to cerebrotendinous xanthomatosis.
Topics: Depressive Disorder; Doxepin; Haloperidol; Humans; Lipidoses; Male; Middle Aged; Neurocognitive Diso | 1983 |
Clinical conferences: Management of depression in older people.
Topics: Aged; Antidepressive Agents; Dementia; Depressive Disorder; Desipramine; Diagnosis, Differential; Do | 1982 |
Hormonal interference in experimental models of depression.
Topics: Animals; Apomorphine; Behavior, Animal; Depressive Disorder; Disease Models, Animal; Haloperidol; Hu | 1982 |
Haloperidol and phobias.
Topics: Adult; Depressive Disorder; Female; Haloperidol; Humans; Phobic Disorders | 1982 |
Further analysis of the specificity of a novel animal model of depression--effects of an antihistaminic, antipsychotic and anxiolytic compound.
Topics: Animals; Corticosterone; Depressive Disorder; Disease Models, Animal; Exploratory Behavior; Haloperi | 1982 |
[Depressive states in schizophrenic in-patients on admission and at discharge (author's transl)].
Topics: Acute Disease; Depressive Disorder; Haloperidol; Hospitals, Psychiatric; Humans; Motivation; Schizop | 1981 |
Personality in unipolar and bipolar manic-malancholic patients.
Topics: Adult; Age Factors; Aged; Antidepressive Agents, Tricyclic; Bipolar Disorder; Depressive Disorder; F | 1980 |
Depression in schizophrenia: clinical and pharmacological variables.
Topics: Adolescent; Adult; Age Factors; Aged; Depressive Disorder; Dexamethasone; Female; Fluphenazine; Halo | 1995 |
Alopecia areata associated with haloperidol.
Topics: Administration, Oral; Alopecia Areata; Antidepressive Agents; Depressive Disorder; Haloperidol; Huma | 1994 |
Three cases of alopecia areata induced by zotepine.
Topics: Adult; Alopecia; Alopecia Areata; Antipsychotic Agents; Autoimmune Diseases; Carbamazepine; Clomipra | 1993 |
Neuroleptic malignant syndrome and catatonia. A report of three cases.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Catatonia; Depressive Disorder; Dibenzothiazepines; D | 1994 |
Pharmacotherapy of delusional depression: experience with combinations of antidepressants with the neuroleptics zotepine and haloperidol.
Topics: Adult; Amitriptyline; Antipsychotic Agents; Delusions; Depressive Disorder; Dibenzothiepins; Dose-Re | 1994 |
Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria.
Topics: Adult; Aged; Akathisia, Drug-Induced; Anxiety Disorders; Depressive Disorder; Dose-Response Relation | 1994 |
Correct titration of non-drugs and some other methodological issues.
Topics: Administration, Oral; Amitriptyline; Anxiety Disorders; Benperidol; Depressive Disorder; Dose-Respon | 1994 |
Neuroleptic dysphoria: in search of an animal model.
Topics: Brain; Depressive Disorder; Domperidone; Haloperidol; Humans; Psychotic Disorders | 1993 |
Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variables.
Topics: Adolescent; Adult; Anxiety Disorders; Brain; Cerebral Ventricles; Depressive Disorder; Dexamethasone | 1994 |
Reduced total complement haemolytic activity in schizophrenic patients.
Topics: Autoimmune Diseases; Bipolar Disorder; Chronic Disease; Complement Activation; Complement C3; Comple | 1993 |
Delirium associated with a combination of sertraline, haloperidol, and benztropine.
Topics: 1-Naphthylamine; Adult; Benztropine; Delirium; Depressive Disorder; Drug Interactions; Drug Therapy, | 1996 |
Drug-induced dysphoria.
Topics: Administration, Oral; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Depressive Disorder; Fem | 1996 |
Antipsychotic drug-induced dysphoria.
Topics: Adult; Akathisia, Drug-Induced; Anti-Dyskinesia Agents; Antipsychotic Agents; Depressive Disorder; F | 1995 |
Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Dipeptidy | 1996 |
Urinary retention with fluoxetine-haloperidol combination in a young patient.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Depressive Disorder; Drug Int | 1996 |
[Depressive stupor--malignant neuroleptic syndrome--serotonin syndrome. A case contribution to a difficult differential diagnosis].
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzamides; Depressive Disorder; Diagnosis, | 1996 |
Phenelzine as a possible treatment for depression in schizophrenic patients.
Topics: Adult; Depressive Disorder; Drug Therapy, Combination; Haloperidol; Humans; Male; Monoamine Oxidase | 1996 |
ECT in genetically confirmed Huntington's disease.
Topics: Aged; Alleles; Amoxapine; Combined Modality Therapy; Depressive Disorder; Electroconvulsive Therapy; | 1996 |
Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol.
Topics: Adult; Body Temperature; Cytokines; Depressive Disorder; Female; Haloperidol; Humans; Leukocyte Coun | 1997 |
Carbamazepine in the treatment of neuroleptic malignant syndrome.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Depressive Disorder; Female; Haloperido | 1998 |
Haloperidol-induced catalepsy: a model for screening antidepressants effective in treatment of depression with Parkinson's disease.
Topics: Animals; Antidepressive Agents; Catalepsy; Depressive Disorder; Drug Evaluation, Preclinical; Halope | 1997 |
Clarithromycin-induced mania.
Topics: Bipolar Disorder; Clarithromycin; Depressive Disorder; Female; Haloperidol; Humans; Lithium; Middle | 1998 |
Medical management of disturbed behaviour.
Topics: Antidepressive Agents; Benzodiazepines; Bipolar Disorder; Chlorpromazine; Depressive Disorder; Dysto | 1998 |
Empirical validation of primary negative symptoms: independence from effects of medication and psychosis.
Topics: Adult; Age of Onset; Antipsychotic Agents; Anxiety Disorders; Basal Ganglia Diseases; Depressive Dis | 1999 |
Electroconvulsive therapy for the treatment of neuroleptic malignant syndrome with psychotic symptoms: a report of five cases.
Topics: Adult; Antipsychotic Agents; Depressive Disorder; Drug Therapy, Combination; Female; Haloperidol; Hu | 1999 |
Ventricular ectopy associated with low-dose intravenous haloperidol and electroconvulsive therapy.
Topics: Aged; Antipsychotic Agents; Depressive Disorder; Electroconvulsive Therapy; Haloperidol; Humans; Mal | 2000 |
Scyllo-inositol in post-mortem brain of bipolar, unipolar and schizophrenic patients.
Topics: Adolescent; Adult; Aged; Animals; Antipsychotic Agents; Bipolar Disorder; Brain; Depressive Disorder | 2000 |
[Malignant neuroleptic syndrome after haloperidol administration].
Topics: Aged; Antipsychotic Agents; Catecholamines; Critical Care; Dantrolene; Depressive Disorder; Haloperi | 2001 |
Lamina-specific deficits in parvalbumin-immunoreactive varicosities in the prefrontal cortex of subjects with schizophrenia: evidence for fewer projections from the thalamus.
Topics: Adult; Age Factors; Aged; Animals; Cause of Death; Cell Count; Depressive Disorder; Female; Haloperi | 2001 |
Prescription of psychopharmaca in common psychiatric diagnoses (discussion on the results of an anonymous survey).
Topics: Antipsychotic Agents; Czechoslovakia; Depressive Disorder; Drug Prescriptions; Haloperidol; Humans; | 1992 |
Coping style and cognitive dysfunction in schizophrenic patients.
Topics: Activities of Daily Living; Adaptation, Psychological; Adult; Arousal; Attention; Chronic Disease; D | 1992 |
[Malignant neuroleptic syndrome: complete anticoagulant treatment or not?].
Topics: Adult; Anticoagulants; Biperiden; Depressive Disorder; Drug Therapy, Combination; Haloperidol; Human | 1992 |
Alopecia and mood stabilizers: two case reports.
Topics: Adult; Alopecia; Carbamazepine; Clorazepate Dipotassium; Depressive Disorder; Female; Fluvoxamine; H | 1992 |
Functional brain asymmetry and visuospatial perception in mania, depression, and psychotropic medication.
Topics: Adult; Bipolar Disorder; Brain; Chlorpromazine; Depressive Disorder; Female; Functional Laterality; | 1992 |
Neuroleptic malignant syndrome presenting as hyperosmolar non-ketotic diabetic coma.
Topics: Body Temperature Regulation; Combined Modality Therapy; Depressive Disorder; Diagnosis, Differential | 1992 |
Tardive dyskinesia in the elderly patient.
Topics: Aged; Chlorpromazine; Chronic Disease; Clonazepam; Clozapine; Depressive Disorder; Desipramine; Diph | 1992 |
Drug-responsive symptoms during early neuroleptic treatment.
Topics: Adult; Benztropine; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Drug Th | 1992 |
Recurrence of neuroleptic malignant syndrome via an inadvertent rechallenge in a woman with mental retardation.
Topics: Adult; Depressive Disorder; Female; Haloperidol; Humans; Intellectual Disability; Neuroleptic Malign | 1992 |
[ICU syndrome].
Topics: Aged; Anxiety; Benzodiazepines; Clomipramine; Critical Care; Delirium; Depressive Disorder; Female; | 1991 |
Crossover reaction between haloperidol and amoxapine for NMS.
Topics: Aged; Amoxapine; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; F | 1991 |
[Clinical study of intractable mental diseases].
Topics: Adolescent; Adult; Antidepressive Agents; Depressive Disorder; Electroencephalography; Epilepsy; Fem | 1991 |
Red blood cell NMR proton relaxation times in ill and recovered patients with unipolar and bipolar affective disorders.
Topics: Bipolar Disorder; Chlorpromazine; Depressive Disorder; Erythrocytes; Female; Haloperidol; Humans; In | 1991 |
Cold agglutinin autoantibodies in psychiatric patients: their relation to diagnosis and pharmacological treatment.
Topics: Adult; Age Factors; Agglutinins; Autoantibodies; Bipolar Disorder; Cryoglobulins; Depressive Disorde | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Haloperidol and lithium carbonate treatment did not influence serum immunoglobulin levels in schizophrenic and affective patients.
Topics: Adolescent; Adult; Bipolar Disorder; Chronic Disease; Depressive Disorder; Female; Haloperidol; Huma | 1991 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
A possible association of Ganser's syndrome and major depression.
Topics: Adult; Depressive Disorder; Dissociative Disorders; Factitious Disorders; Female; Haloperidol; Human | 1990 |
Thyroid hormone elevations during acute psychiatric illness: relationship to severity and distinction from hyperthyroidism.
Topics: Adult; Bipolar Disorder; Blood Pressure; Depressive Disorder; Down-Regulation; Feedback; Female; Hal | 1990 |
Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients.
Topics: Aged; Antidepressive Agents; Cognition Disorders; Depressive Disorder; Drug Interactions; Drug Thera | 1990 |
Serum haloperidol and desipramine concentrations and the treatment of psychotic depression: two case reports.
Topics: Adult; Depressive Disorder; Desipramine; Female; Haloperidol; Humans | 1989 |
Visual contrast sensitivity in drug-induced Parkinsonism.
Topics: Adolescent; Adult; Bipolar Disorder; Depressive Disorder; Drug Therapy, Combination; Female; Fluspir | 1989 |
The TRH test during dopamine receptor blockade in depressed patients.
Topics: Adult; Brain; Depressive Disorder; Dopamine; Female; Haloperidol; Humans; Male; Middle Aged; Pituita | 1986 |
The effects of carbamazepine on two animal models of depression.
Topics: Animals; Carbamazepine; Depressive Disorder; Disease Models, Animal; Haloperidol; Imipramine; Male; | 1987 |
Drug-induced catatonia.
Topics: Aged; Aged, 80 and over; Catatonia; Dementia; Depressive Disorder; Drug Therapy, Combination; Female | 1988 |
"At risk" group for neuroleptic malignant syndrome.
Topics: Adult; Depressive Disorder; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Risk Factors | 1988 |
Effect of ketoconazole on a hypophysectomized, hypercortisolemic, psychotically depressed woman.
Topics: Adult; Depressive Disorder; Dexamethasone; Female; Haloperidol; Humans; Hydrocortisone; Hypophysecto | 1988 |
[Depressive syndromes within the scope of schizophrenic diseases].
Topics: Clozapine; Depressive Disorder; Haloperidol; Humans; Risk; Schizophrenia; Schizophrenic Psychology | 1986 |
Rapid normalization of the dexamethasone suppression test with mianserin.
Topics: Chlorpromazine; Depressive Disorder; Dexamethasone; Haloperidol; Humans; Hydrocortisone; Mianserin; | 1987 |
[Value of neuroleptic therapy in the self assessment of schizophrenic patients].
Topics: Clozapine; Depressive Disorder; Dibenzazepines; Dyskinesia, Drug-Induced; Haloperidol; Humans; Psych | 1987 |
Neuroleptic dose and desipramine concentrations during combined treatment of unipolar delusional depression.
Topics: Administration, Oral; Adult; Aged; Delusions; Depressive Disorder; Desipramine; Drug Administration | 1986 |
Neuroleptic-induced neutropenia in the elderly.
Topics: Aged; Agranulocytosis; Depressive Disorder; Female; Granulocytes; Haloperidol; Humans; Leukocyte Cou | 1987 |
Relationship between neuroleptic malignant syndrome and malignant hyperthermia.
Topics: Atracurium; Basal Ganglia Diseases; Depressive Disorder; Electroconvulsive Therapy; Haloperidol; Hum | 1985 |
Combined use of tricyclic antidepressants and neuroleptics in the management of terminally ill children: a report on three cases.
Topics: Adolescent; Amitriptyline; Anxiety Disorders; Child; Depressive Disorder; Drug Therapy, Combination; | 1985 |